Vimpat

RSS

lacosamide

Authorised
This medicine is authorised for use in the European Union.

Overview

Vimpat is a medicine used on its own or as an add-on to other epilepsy medicines in the treatment of partial-onset seizures (epileptic fits starting in one specific part of the brain) with or without secondary generalisation (where the abnormal electrical activity spreads through the brain) in patients with epilepsy aged 4 years and older

Vimpat can also be used as add-on to other epilepsy medicines in the treatment of primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 4 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

Vimpat contains the active substance lacosamide.

This EPAR was last updated on 18/02/2021

Authorisation details

Product details
Name
Vimpat
Agency product number
EMEA/H/C/000863
Active substance
lacosamide
International non-proprietary name (INN) or common name
lacosamide
Therapeutic area (MeSH)
Epilepsy
Anatomical therapeutic chemical (ATC) code
N03AX18
Publication details
Marketing-authorisation holder
UCB Pharma SA
Revision
34
Date of issue of marketing authorisation valid throughout the European Union
29/08/2008
Contact address
Allée de la Recherche 60
BE-1070 Brussels
Belgium

Product information

01/12/2020 Vimpat - EMEA/H/C/000863 - WS/1782

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antiepileptics

Therapeutic indication

Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
1 rating